Mitochon Pharmaceuticals » Logo
Mitochon Pipeline
Mitochon Pipeline
Preclinical Efficacy
IND Enabling Activities
Phase I
Phase II

Multiple Sclerosis

No known etiology.
Autoimmune disorder of the CNS.
Antibodies attack the myelin sheaths surrounding and protecting the axons.
Intermitting episodes, called Relapsing Remitting, the body repairs itself to some degree.
Chronic attacks, called Progressive, is the most severe where axons/neurons die off.
Voluntary movement is disrupted and involuntary control of bladder and bowels.

Our Data Shows:

MP101 and MP201 significantly improve Clinical Scores (block paralysis) in the gold standard EAE model.
MP101 and MP201 prevents demyelination and destruction of the axon in the autoimmune independent cuprizone model.
MP101 and MP201 have a striking effect in preserving body movement and behavior compared to placebo (video).

Video of Multiple Sclerosis mouse model with MP101 and MP201.

MP101 and MP201 attenuates Multiple Sclerosis using the EAE Model.

MP101 and MP201 Attenuates Multiple Sclerosis » Mitochon Pharmaceuticals

*P values by Ordinal Regression
MP101 5mpk = 0.0192
MP201 80mpk = 0.00014

MP101 and MP201 Protect of Axons in Cuprizone Model.

MP101 and MP201 Protect OF Axons » Mitochon Pharmaceuticals

MP101 and MP201 has a striking effect protecting against both demyelination and axonal loss in the autoimmune independent cuprizone model compared to placebo.